Cargando…

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients

SIMPLE SUMMARY: While latest evidence suggests that some patients with recurrent high-grade serous ovarian cancer may profit from reinduction with platinum-based chemotherapy regimens, the selection of patients who are likely to respond remains difficult. The present study therefore aimed to adapt a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartl, Thomas, Karacs, Jasmine, Kreuzinger, Caroline, Pfaffinger, Stephanie, Kendler, Jonatan, Ciocsirescu, Cristina, Wolf, Andrea, Reinthaller, Alexander, Meyer, Elias, Brandstetter, Maximilian, Postl, Magdalena, Langthaler, Eva, Braicu, Elena, Vergote, Ignace, Cunnea, Paula, Gourley, Charlie, Schmitt, Wolfgang D., Cacsire Castillo-Tong, Dan, Christoph, Grimm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959281/ https://www.ncbi.nlm.nih.gov/pubmed/33802395 http://dx.doi.org/10.3390/cancers13051076

Ejemplares similares

SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer
por: Koller, Stephanie, et al.
Publicado: (2022)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
por: Obermayr, Eva, et al.
Publicado: (2017)

Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer
por: Mungenast, Felicitas, et al.
Publicado: (2017)

The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer
por: Bartl, Thomas, et al.
Publicado: (2020)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Successful one-stage resection of intracardiac intravenous leiomyomatosis: A case report
por: Magdalena, Postl, et al.
Publicado: (2023)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report
por: Paspalj, V., et al.
Publicado: (2021)

Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer
por: Van Nieuwenhuysen, Els, et al.
Publicado: (2019)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Prognostic value of serum creatine level in patients with vulvar cancer
por: Schwameis, Richard, et al.
Publicado: (2019)

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
por: Friedlander, Michael, et al.
Publicado: (2018)

Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer
por: Lu, Haonan, et al.
Publicado: (2021)

The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate
por: Bekos, Christine, et al.
Publicado: (2022)

AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer
por: Svoboda, Martin, et al.
Publicado: (2016)

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
por: Hollis, Robert L., et al.
Publicado: (2022)

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
por: Aust, Stefanie, et al.
Publicado: (2020)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer
por: Meshcheryakova, Anastasia, et al.
Publicado: (2019)

Ovarian cancer and the immune system
por: Baert, Thaïs, et al.
Publicado: (2017)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive
por: Gourley, Charlie
Publicado: (2019)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Pre-operative hypoalbuminemia is associated with complication rate and overall survival in patients with vulvar cancer undergoing surgery
por: Bekos, Christine, et al.
Publicado: (2019)

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study
por: Watrowski, Rafał, et al.
Publicado: (2022)

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
por: Braicu, Elena Ioana, et al.
Publicado: (2017)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification
por: Olbrecht, Siel, et al.
Publicado: (2021)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium
por: Obermayr, Eva, et al.
Publicado: (2021)

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
por: Tomar, Tushar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ff0r8h2akod1899leuf9u1m7ip